bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pancoronavirus antiviral potential
Neha Vithani1,2*, Michael D. Ward1,2*, Maxwell I. Zimmerman1,2, Borna Novak1,2,3,
Jonathan H. Borowsky1,2, Sukrit Singh1,2, Gregory R. Bowman1,2‚Ä†
1Department

of Biochemistry and Molecular Biophysics, Washington University School of
Medicine, St. Louis, Missouri 63110, United States
2Center for Science and Engineering of Living Systems (CSELS), Washington University
in St. Louis, St. Louis, Missouri 63130, United States
3Medical Scientist Training Program, Washington University in St. Louis School of
Medicine, St. Louis, Missouri 63110, United States

*These authors contributed equally to this work.
‚Ä†Corresponding Author: g.bowman@wustl.edu

Running title: Nsp16 activation mechanism and cryptic pocket

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Abstract
Coronaviruses have caused multiple epidemics in the past two decades, in addition to the
current COVID-19 pandemic that is severely damaging global health and the
economy. Coronaviruses employ between twenty and thirty proteins to carry out their viral
replication cycle including infection, immune evasion, and replication. Among these,
nonstructural protein 16 (Nsp16), a 2‚Äô-O-methyltransferase, plays an essential role in
immune evasion. Nsp16 achieves this by mimicking its human homolog, CMTr1, which
methylates mRNA to enhance translation efficiency and distinguish self from other. Unlike
human CMTr1, Nsp16 requires a binding partner, Nsp10, to activate its enzymatic activity.
The requirement of this binding partner presents two questions that we investigate in this
manuscript. First, how does Nsp10 activate Nsp16? While experimentally-derived
structures of the active Nsp16/Nsp10 complex exist, structures of inactive, monomeric
Nsp16 have yet to be solved. Therefore, it is unclear how Nsp10 activates Nsp16. Using
over one millisecond of molecular dynamics simulations of both Nsp16 and its complex
with Nsp10, we investigate how the presence of Nsp10 shifts Nsp16‚Äôs conformational
ensemble in order to activate it. Second, guided by this activation mechanism and Markov
state models (MSMs), we investigate if Nsp16 adopts inactive structures with cryptic
pockets that, if targeted with a small molecule, could inhibit Nsp16 by stabilizing its
inactive state. After identifying such a pocket in SARS-CoV-2 Nsp16, we show that this
cryptic pocket also opens in SARS-CoV-1 and MERS, but not in human CMTr1.
Therefore, it may be possible to develop pan-coronavirus antivirals that target this cryptic
pocket.

Statement of Significance
Coronaviruses are a major threat to human health. These viruses employ molecular
machines, called proteins, to infect host cells and replicate. Characterizing the structure
and dynamics of these proteins could provide a basis for designing small molecule
antivirals. In this work, we use computer simulations to understand the moving parts of
an essential SARS-CoV-2 protein, understand how a binding partner turns it on and off,
and identify a novel pocket that antivirals could target to shut this protein off. The pocket
is also present in other coronaviruses but not in the related human protein, so it could be
a valuable target for pan-coronavirus antivirals.

Introduction
With the coronavirus 2019 (COVID-19) pandemic ravaging communities across the globe
there is a massive ongoing effort to understand the molecular machinery of
coronaviruses, which may provide insight into therapeutic opportunities (1‚Äì3). The severe
acute respiratory syndrome coronavirus 2 (SARS-CoV2) virus responsible for COVID-19
disease has infected over sixty million and killed over 1.5 million people globally to date
(4). Additionally, coronaviruses have caused several past epidemics including severe
acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) which
had fatality rates of ~10% and ~34%, respectively (5, 6). Therefore, there is likely to be
evolution and outbreaks of additional zoonotic coronaviruses in the future (7). While

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

vaccine trials for COVID-19 are successfully wrapping up, there are still no approved
antivirals that reduce mortality to coronavirus infections (8‚Äì10). Taken together, there is
strong incentive to understand the fundamental mechanisms of how these coronaviruses
operate in hopes of discovering effective therapeutics. Biophysical studies can provide
these details, and a tremendous amount of biophysical work has already been done to
understand the virus‚Äô twenty-nine proteins. So far, the spike protein, positioned on the
outside of the viral envelope, has proven to be a good vaccine candidate (11). Beyond
the spike, the sixteen ‚Äúnonstructural‚Äù (i.e. accessory) proteins carry out the majority of the
virus‚Äô essential processes, making them good targets for antiviral therapeutics (12, 13).
Among the nonstructural proteins (Nsp‚Äôs), Nsp16 is particularly important to the
viral replication cycle as it is essential to coronavirus‚Äô immune evasion (14‚Äì16). Nsp16 is
a 2‚Äô-O-Methyltransferase (2‚Ä≤-O-MTase) that forms part of the replication-transcription
complex (17). It mimics the human protein Cap-specific mRNA (nucleoside-2'-O-)methyltransferase (CMTr1) to perform a crucial step in capping transcribed mRNA (18).
Specifically, Nsp16 facilitates the transfer of a methyl group from its Sadenosylmethionine (SAM) cofactor to the 2‚Äô hydroxyl of ribose sugar of viral mRNA (18,
19). This methylation both improves translation efficiency and camouflages the mRNA so
that it is not recognized by intracellular pathogen recognition receptors, such as IFIT and
RIG-I (15, 20). Importantly, inhibiting or knocking out 2‚Ä≤-O-MTase activity severely
attenuates viral replication and infectivity of coronaviruses (13, 20). Thus, developing
small molecules inhibitors of Nsp16 is a promising therapeutic strategy.
Interestingly, while all other 2‚Ä≤-O-MTases (eukaryotic and viral) are active as
monomers, Nsp16 requires a binding partner, Nsp10, to be active (16‚Äì18, 21‚Äì23). In fact,
Nsp16 does not even bind its ligands (SAM and RNA) in the absence of Nsp10. In the
experimentally-derived structures of the Nsp16/Nsp10 complex, Nsp10 does not form any
direct interaction with either ligand (Fig. 1a), suggesting that Nsp10 may allosterically
regulate Nsp16 to enable substrate binding (18, 19, 24‚Äì27). Given that there is significant
structural variation in the RNA-binding loops of different crystal structures of Nsp16 (Fig.
1b) and structures of monomeric Nsp16 have not been solved, we hypothesized that
Nsp16 is highly dynamic in solution, and Nsp10 acts by stabilizing the active state. In
contrast, we anticipate that human CMTr1 would be less dynamic as it doesn‚Äôt require a
binding partner for substrate binding and has been crystalized in its monomeric state.
Often, dynamics of proteins reveal allosteric pockets that remain hidden in their crystal
structures (i.e., cryptic pockets). If monomeric Nsp16 is more dynamic than CMTr1, it may
adopt inactive configurations that reveal allosteric cryptic pockets, which can be targeted
by small-molecule inhibitors for its selective inhibition.
Here, we use computer simulations to understand the activation mechanism of
Nsp16 and identify cryptic pockets that may be valuable antiviral targets. Active site
inhibitors, such as Sinefungin, have been shown to outcompete SAM binding and render
Nsp16 catalytically inactive (28, 29). However, there are more than 200 human proteins
with known or putative methyltransferase activity that use SAM as a cofactor (30).
Therefore, it may be difficult to design antivirals that target the SAM (or RNA) binding
sites of Nsp16 without eliciting off-target effects by also binding human

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

methyltransferases. For example, Sinefungin has been shown to occupy the SAM-binding
pocket of human N7 methyltransferase in a crystal structure (PDB: 3epp). Targeting the
Nsp16/Nsp10 interface could be an alternative means to selectively inhibit Nsp16 since
CMTr1 lacks a homologous binding partner. Towards this, peptide-based inhibitors that
mimic Nsp10 to compete for interactions at the Nsp10/Nsp16 interface have been shown
to inhibit Nsp16 activity (31, 32). While this approach seems promising, peptide-based
inhibitors face challenges including limited stability and shelf-life, the possibility of adverse
immunogenic responses, and the high cost of production (33). To expand the therapeutic
opportunities, we search for other ways to inactivate Nsp16. First, we compare the
structure and dynamics of SARS-CoV2 Nsp16 in the presence and absence of Nsp10 to
understand Nsp16‚Äôs activation. Specifically, we use over one millisecond of molecular
dynamics simulation data (2) to characterize how Nsp10 binding shifts Nsp16‚Äôs
conformational ensemble to activate Nsp16. After showing that the resulting model is
consistent with a variety of experimental observations, we use it to hunt for cryptic pockets
that may provide a means to inhibit Nsp16. Finally, we extend our simulations to SARSCoV-1, MERS, and human CMTr1 to determine if targeting such a pocket could provide
an opportunity to develop pan-coronavirus antivirals.

Figure 1. Substrate binding pockets and Nsp10 binding interface of Nsp16 observed in
the crystal structure of the Nsp16/Nsp10 complex (PDB: 6wks). (A) Surface
representation of Nsp16 showing the SAM-binding pocket (cyan), RNA-binding pocket
(yellow) and Nsp10-binding interface (green). (B) Overlay of Nsp16 structures from
structures of the Nsp16/Nsp10 complex with RNA (PDB: 6wks, shown in grey) and
without RNA (PDB: 6w4h, shown in cyan), showing structural heterogeneity in the RNAbinding site. Gate loop 1 and Gate loop 2 of the RNA-binding pocket, and SAM-binding
loop 1 (SAMBL1) and SAM-binding loop 2 (SAMBL2) lining the SAM-binding pocket are
highlighted.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Results and Discussion
Nsp10 promotes opening of Nsp16‚Äôs SAM- and RNA-binding pockets
While experimental studies have demonstrated that Nsp16 requires Nsp10 to be
functionally active, the structural determinants of Nsp16‚Äôs activation remain unknown (17,
18, 23). Chen et. al. proposed that Nsp10‚Äôs stimulatory effects are rooted in its ability to
assist Nsp16 in binding SAM and RNA, which is supported by data showing that Nsp16
alone cannot bind SAM or RNA (18). They also propose that Nsp10 manages this by
stabilizing or changing the conformation of the SAM binding pocket based on the fact that
Nsp10 contacts SAM binding loops in their crystal structure (and numerous other
structures). However, without assessing Nsp10-Nsp16 complex‚Äôs dynamics and
comparing it to monomeric Nsp16, this hypothesis is left wanting. It has also been
proposed that Nsp10 assists in RNA binding by directly contacting RNA (34). However, a
recent crystal structure with RNA bound (PDB: 7jyy) contains a stretch of nucleotides long
enough to contact Nsp10, but the RNA curls off into solution instead of interacting with
Nsp10. Another recent study compared an RNA and SAM bound Nsp10/16 complex
structure to one with only SAM bound and found a major opening of RNA binding gate
loops suggesting that the dynamics of these loops might be important for Nsp16 activation
(25). However, it is not clear if Nsp10 plays a role in those dynamics. Altogether, there is
strong evidence that Nsp10 modulates Nsp16‚Äôs structure and dynamics to assist it in
binding SAM and RNA, but the mechanism of these structural changes is unclear.
To explore how Nsp10 activates Nsp16, we analyzed simulations of Nsp16 in the
presence and absence of Nsp10 using DiffNets. Recently, our group combined the
sampling powers of the FAST-pockets adaptive sampling algorithm (35) and the
computational resources of Folding@home to accumulate more than one millisecond of
simulation data between simulations of monomeric Nsp16 and the Nsp16/Nsp10 complex
(see methods) (2). Here, we compare these simulations using a deep learning-based
dimensionality reduction algorithm called DiffNets (36). DiffNets has been shown to
accurately capture the structural determinants of biochemical differences between protein
variants. While we are not considering protein variants, our problem is similar since Nsp16
has different biochemical properties when in the presence/absence of Nsp10 (i.e.
active/inactive). Therefore, we trained a DiffNet to learn the structural determinants of
Nsp16 activation by learning differences between Nsp16‚Äôs ensemble when in the
presence and absence of Nsp10. For each simulation frame, the DiffNet learns a low
dimensional projection of the protein structure and classifies the structure with a label
between 0 and 1 that indicates the likelihood that the structure is associated with Nsp16
being active.
Analysis of the DiffNet suggests that Nsp10 shifts Nsp16‚Äôs conformational
ensemble to stabilize more open SAM- and RNA-binding pockets. Using the DiffNet
classification labels, we identified ten structures that are representative of the progression
from Nsp16 inactive states to active states (see methods and Fig. 2). We noticed that
RNA gate loop 2 moves away from RNA gate loop 1, making for a more open RNA binding
pocket in active states compared to inactive states (Fig. 2A). Additionally, the SAMbinding pocket also opens up in the active states relative to the inactive states. RNA-

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

binding gate loop 2 and SAM-binding loop 2 move away from each other in the active
state, which widens the pocket creating space for SAM. (Fig. 2A). Strikingly, the structure
associated with the highest label (i.e. most strongly associated with Nsp16 activation)
matches well to a recently solved crystal structure that is bound to both RNA and SAM
(Fig. 2B) (25). This DiffNet result is encouraging since the simulations were started from
a markedly different crystal structure (no RNA bound) and had no a priori information
about the RNA bound structure. This result implies that the DiffNet learned that Nsp10
activates Nsp16, in part, by rearranging the RNA gate loop into an RNA binding
competent pose. Though it is known that this RNA gate loop needs to open to bind RNA,
this is the first evidence, to our knowledge, to suggest that Nsp10 may activate Nsp16
through increasing its propensity to form a more open RNA-binding pocket. Altogether,
these results suggest that Nsp10‚Äôs presence increases the propensity for both SAM- and
RNA- binding pockets to be open.

Figure 2. Nsp10 binding shifts Nsp16‚Äôs conformational ensemble increasing its
propensity to adopt structural states that are ligand binding compatible. (A) Ten structures
of Nsp16 that represent the DiffNet prediction changing from inactive to active (white to
purple). (B) Comparison of the DiffNet predicted active state (purple) to the starting
simulation state (yellow) and a known RNA bound structural state (orange). (C)
Probability-weighted distance distribution between RNA-binding gate loops 1 and 2

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

comparing monomeric Nsp16 (black) to the Nsp10-Nsp16 complex (gray). (D) Probabilityweighted distance distribution between SAM-binding loop 2 and gate loop 2, comparing
monomeric Nsp16 (black) to the Nsp10-Nsp16 complex (gray). For (C) and (D), the
distance for a SAM and RNA bound crystal structure is also plotted (red dotted line).

To quantify the effect of Nsp10 on the SAM- and RNA-binding pockets, we built
MSMs for both the complex and monomeric Nsp16. MSMs are a statistical framework for
analyzing molecular dynamics simulation data that provide (among other things) a
discrete map of structural configurations, an equilibrium population value that
corresponds to the proportion of time a protein spends in any given configuration, and the
probability of transitioning between any pair of configurations (37). We constructed MSMs
for Nsp16 simulations both in the presence and absence of Nsp10.

Our MSMs reveal that Nsp10 binding stabilizes open structures of both the SAMand RNA-binding pockets that are competent to bind their respective substrates. We first
found that the presence of Nsp10 results in a substantial reduction of flexibility in
important binding components including both SAM binding loops and RNA gate loops
(see SI, Fig. S1). This result is somewhat surprising since gate loop 2, which contacts
both SAM and RNA, is not in direct contact with Nsp10, suggesting strong allosteric
communication. Next, we calculated the distribution of distances for opening and closing
of the SAM and RNA binding pockets (Fig. 2C,D). From these histograms it is clear that
both of these binding pockets have an increased propensity to open when Nsp10 is
present. We considered pockets as SAM/RNA binding competent when the distance
between loops in a pocket is at least as open as in the crystal structure that binds both
ligands (PDB: 6wks). From this analysis, Nsp16 adopts binding competent states with
higher probability when Nsp10 is present vs when Nsp10 is absent for both SAM (0.70 ¬±
0.04 vs 0.46 ¬± 0.04) and RNA (0.48 ¬± 0.04 vs 0.27 ¬± 0.03). Altogether, our data suggest
that Nsp10 aids SAM and RNA binding by preventing the collapse of SAM and RNA
binding gate loops. Our analysis also provides structural snapshots of what inactive states
look like, which may be useful in targeting Nsp16 with therapeutics.

A cryptic pocket in Nsp16 is a potential therapeutic target
A traditional approach to drug development involves molecules designed to target binding
cavities observed in singular structural snapshots of a protein, but this approach often
misses ‚Äúcryptic‚Äù pockets that can form in proteins due to thermal fluctuations. Often times
the active site of an enzyme is targeted for drug development to design an inhibitor that
can outcompete substrate binding. However, active sites are often conserved among
functional homologs. In the case of Nsp16, its human homolog (CMTr1) shares the same
overall fold and binds the same substrates. Though there are significant sequence and
structural differences in the active site, specificity may be more easily achieved by
targeting a less functionally relevant region of the protein. Cryptic pockets can provide

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

both a new target for drug development and the potential to achieve specificity. For
example, cryptic pockets that remain closed and invisible in the crystal structure, but open
in solution due to thermal fluctuations (38), can present unique potential binding sites due
to differences in the dynamics of subsets of homologs (e.g. open in coronavirus
homologs, but closed in human CMTr1). Therefore, it may be easier to achieve specificity
by targeting a cryptic pocket. Importantly, the cryptic pocket must communicate with
functional sites in order for it to be an effective therapeutic target. Here, we explore if
Nsp16 contains any cryptic pockets that, when open, would stabilize the inactive state
identified with DiffNets.

Figure 3. Cryptic pocket opening in SARS-CoV-2 Nsp16. (A) Structural states with the
cryptic pocket closed and open. The insets show surface views of the closed and open
pocket. Residues exposed upon pocket opening are shown in cyan and the regions
undergoing the opening motion are shown in blue. Collapse of the SAM-binding pocket
is measured as the distance between SAMBL2 and gate loop 2, shown in yellow. (B)
Equilibrium probability weighted 2D histograms of solvent-accessible surface area
(SASA) of pocket residues (shown in cyan in A) and the distance between SAMBL2 and
gate loop 2 in Nsp16 for monomeric Nsp16 (upper panel) and the Nsp16/Nsp10 complex
(lower panel). The black dotted line separates the pocket closed and open states in
Nsp16.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

To find cryptic pockets, we applied ‚ÄúExposons‚Äù, an algorithm (38) that identifies
residues with cooperative changes in solvent exposure, to Nsp16 simulation data. Using
this method, we found that residues in the Œ≤3 strand and …ë3 helix transition between
closed states and open states (i.e. low to high solvent accessible surface area) (Figure
3A). Specifically, the Œ≤4 strand curls up to form an …ë-helical structure, which results in
surface exposure of Œ≤3 and residues from …ë3 (Fig. 3A). The opening motion of Œ≤4 shifts
the adjacent SAMBL2 against gate loop 2 to collapse the SAM binding pocket in a closed
conformation (Fig. 3A,B). This agrees with the DiffNet prediction that the Œ≤4 strand moving
away from Œ≤3 is associated with inactivation (see SI. Fig. S2). Further, several residues
forming this cryptic pocket directly contact Nsp10 in crystal structures of the Nsp16/Nsp10
complex (see SI. Fig. S3). The Œ≤3-Œ≤4 pocket opening displaces these Nsp10 binding
residues, which could inhibit Nsp16‚Äôs association with Nsp10 (see SI. Fig. S3). Finally,
we find that this open pocket structure is commonly visited as part of monomeric Nsp16‚Äôs
conformational ensemble, as measured with MSM equilibrium populations (Fig. 3B).
Taken together, we propose that targeting the Œ≤3-Œ≤4 pocket with a small molecule could
inhibit Nsp16‚Äôs activity by preventing SAM binding or preventing association with Nsp10.

Conservation of the cryptic pocket in Nsp16 makes it a promising target for broadspectrum inhibitors
To explore the possibility of targeting the cryptic pocket for broad-spectrum inhibition of
coronaviruses, we evaluated the conservation of cryptic pocket opening in Nsp16
homologs. Ideally, a therapeutic developed to treat SARS-CoV-2 would also work against
other coronaviruses like MERS, SARS-CoV-1, and potentially future outbreaks.
Additionally, the therapeutic target should be sufficiently dissimilar from human CMTr1
such that it would not cause unwanted, off-target effects. While we identified a promising
cryptic pocket in SARS-CoV-2, we wanted to investigate if this pocket is specific to SARSCoV-2, or specific to coronaviruses in general, or if it is common across homologs
including CMTr1.
First, we analyze cryptic pocket conservation by comparing sequence features and
structural features based on the native, folded state. We find that the Œ≤3-Œ≤4 pocket
residues are 100% conserved between SARS-CoV-2 and SARS-CoV-1 (Fig. 4B).
Additionally, of the eleven residues that form the pocket, there are only two nonconservative mutations between SARS-CoV-2 and MERS. Based on the sequence
similarity, we expect that, if the cryptic pocket forms in all homologs, it may be possible
to develop small-molecule therapeutics that targets all three. Further, we find substantial
sequence differences between SARS-CoV-2 and CMTr1. Eight out of the eleven pocket
residues are non-conservative mutations relative to SARS-CoV-2. Based on sequence
differences alone, we reason that selective inhibition could be achieved even if the cryptic
pocket is adopted by CMTr1. Moreover, the sequences and structure of SARS-CoV-2
Nsp16 and human CMTr1 are sufficiently different in the Œ≤3-Œ≤4 pocket region that the
human protein may not even have the cryptic pocket (SI, Fig. S4). Based on these
sequence and structural differences, combined with the lack of requirement of a

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

stabilizing binding partner, we hypothesized that cryptic pocket opening is not likely to be
conserved in CMTr1.
To explore cryptic pocket opening across homologs, we performed FAST-pocket
simulations of monomeric Nsp16 for SARS-CoV1 and MERS, as well as, for human
CMTr1. Then, we built an MSM for each homolog and measured opening of the Œ≤3-Œ≤4
pocket by measuring the equilibrium weighted solvent exposure of the pocket residues
we previously used to define the pocket (i.e. Fig. 3). In these simulations, we find that the
Œ≤3-Œ≤4 pocket opens with high probability in both SARS-CoV1 and MERS Nsp16 (Fig. 4).
Interestingly, the pocket is most likely to open in SARS-CoV-1, followed by SARS-CoV2, then MERS. Encouragingly, we find that the Œ≤3-Œ≤4 pocket has a substantially lower
probability of opening in CMTr1. Taken together, features of the Œ≤3-Œ≤4 cryptic pocket in
coronavirus homologs of Nsp16 appear sufficiently similar to each other and dissimilar to
CMTr1 to make for a promising target for pan-coronavirus inhibitors.

Figure 4. Comparison of cryptic pocket opening in Nsp16 homologs and human CMTr1.
(A) Equilibrium probability-weighted distribution of the solvent exposure of pocket forming
residues for SARS-CoV2 (black), SARS-CoV1 (blue), MERS (red) and CMTr1 (cyan).
Structures representing the open pocket are shown for each homolog with Œ≤3 colored in
cyan, and other pocket forming residues from alpha3 colored in green. Black dotted line

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

depicts SASA of pocket residues in the crystal structure of Nsp16/Nsp10 complex (PDB:
6wks). (B) Structure-based sequence alignment of Nsp16 homologs (SARSCoV2, SARS-CoV1 and MERS) and human CMTr1 is shown for the cryptic pocket
forming regions. Residues of Beta3 are are marked inside the black colored box, and
other pocket forming residues from alpha3 are by green colored stars.

Conclusions
Our work provides mechanistic insight into how Nsp16 is activated and reveals a new
opportunity for inhibiting this essential viral component that could provide a target for pancoronavirus antivirals. First, we elucidate the activation mechanism of Nsp16 by
comparing its dynamics in the presence and absence of its activator, Nsp10. Our results
are consistent with previous experimental findings that Nsp16 cannot bind its substrates
SAM or RNA in the absence of Nsp10 (18). We provide a structural rationale for this
observation by elucidating the structural dynamics of Nsp16 in its monomeric state, which
has remained inaccessible to experimental studies, and comparing it to the structural
dynamics of the Nsp16/Nsp10 complex. Here, we find that Nsp10 activates Nsp16 by
opening its SAM and RNA binding loops, allowing them to accommodate their respective
ligands. Guided by this activation mechanism, we identify structural states of Nsp16 that
are incompatible with substrate binding and also contain potential drug binding sites.
Specifically, we find a pocket formed between Œ≤3 and Œ≤4 of Nsp16 that collapses the SAM
binding pocket when open. The region of the pocket has overlap with where Nsp10 binds
to Nsp16, so targeting this cryptic pocket could inhibit both substrate (SAM) and Nsp10
binding. Therefore, this cryptic site is a promising target for small-molecule inhibitor
development. Further, we find that this cryptic pocket is conserved in MERS and SARSCoV1 Nsp16, but not in the human homolog CMTr1, suggesting its potential for
development of a pan-coronavirus, broad-spectrum inhibitor that may be efficacious
against COVID19 and yet unseen coronavirus outbreaks.

Methods
System Preparation
The systems were prepared starting from crystal structures 6w4h, 3r24, 5ynf and 4n49,
for SARS-CoV-2, SARS-CoV-1, MERS, and CMTr1, respectively. All ligands, solutes, and
water molecules from the crystal structures were removed. For monomeric Nsp16
simulations, Nsp10 was also removed. In the coronavirus homologs, two zinc ions were
retained, and the coordinating residues were modified accordingly (CYS->CYM and HIS>HID). Missing residues in the crystal structure of CMTr1 were modeled using the
Modeller package (39). All systems were solvated in TIP3P water (40) in a rhombic
dodecahedral box with periodic boundary conditions and Na + and Cl- ions added to
neutralize the system. Then, systems were energy minimized with a steepest descent
algorithm until the maximum force fell below 100 kJ/mol/nm using a step size of 0.01 nm
and a cutoff distance of 1.2 nm for the neighbor list, Coulomb interactions, and van der
Waals interactions.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Systems were equilibrated for 1.0 ns in NPT simulations, with all bonds
constrained using the LINCS algorithm (41) and virtual sites were used to allow a 4 s time
step. Cutoffs of 1.1 nm were used for the neighbor list with 0.9 for Coulomb and van der
Waals interactions. The particle mesh Ewald method (42) was employed for treatment of
long-range interactions with a Fourier spacing of 0.12 nm. The Verlet cutoff scheme was
used for the neighbor list. Berendsen barostat was used to control the pressure during
the equilibration.(43) The stochastic velocity rescaling (v-rescale) thermostat was used to
control the temperature at 300 K (44).
Adaptive sampling simulations
The FAST algorithm (35, 45) was employed for all four homologs for a total of five FAST
simulations (SARS-CoV-2 FAST simulations were performed on both monomeric Nsp16
and the Nsp10/Nsp16 complex). FAST was used here to generally enhance
conformational sampling and also to quickly explore cryptic pockets. The procedure for
FAST simulations is as follows: 1) run initial simulations, 2) build MSM, 3) rank states
based on FAST ranking, 4) restart simulations from the top ranked states, 5) repeat steps
2-4 until ranking is optimized. For each system, MSMs were generated after each round
of sampling using a k-centers clustering algorithm based on the RMSD between select
atoms. Clustering continued until the maximum distance of a frame to a cluster center fell
within a predefined cutoff. In addition to the FAST ranking, a similarity penalty was added
to promote conformational diversity in starting structures, as has been described
previously (46).
For SARS-CoV-2 monomeric Nsp16 and Nsp16/Nsp10, the simulation data was
generated in a previous manuscript published by our group. Briefly, FAST-pocket
simulations were run at 300 K for 6 rounds, with 10 simulations per round, where each
simulation was 40 ns in length (2.4 Œºs aggregate simulation for each system). The FASTpocket ranking function favored restarting simulations from states with large pocket
openings. Pocket volumes were calculated using the LIGSITE algorithm (47). From these
simulations, a conformationally diverse set of structures was selected to be run on
Folding@home based on the k-centers clustering algorithm mentioned above. A total of
283 microseconds and 770 microseconds of aggregate simulation time was collected for
the Nsp10/Nsp16 complex and monomeric Nsp16, respectively.
FAST-distance simulations were used for SARS-CoV-1 Nsp16, MERS Nsp16, and
CMTr1 to sample the Œ≤3-Œ≤4 pocket identified from SARS-CoV-2 simulations. FASTdistance simulations were run at 300 K for 15 rounds, with 10 simulations per round,
where each simulation was 40 ns in length (6.0 Œºs aggregate simulation for each system).
The FAST-distance ranking favored stated with greater distances between the alpha
carbons of Œ≤3 and Œ≤4.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

DiffNets
We used DiffNets, a deep learning-based dimensionality reduction algorithm developed
by our group, to highlight biochemically relevant differences between datasets. (36) We
trained a DiffNet to compare and contrast structure ensembles of monomeric Nsp16 and
the Nsp16/Nsp10 complex to find features that discriminate them, highlighting the
structural determinants of Nsp16 activation. First, we subsampled the data by a factor of
25 and 68 for the Nsp16/Nsp10 complex and monomeric Nsp16 data, respectively to have
an equal amount of data. Then, we converted simulation data to DiffNet input following
the data normalization procedure from the original manuscript. Briefly, XYZ atom
coordinates from simulations were mean-shifted to zero, and then multiplied by the
inverse of the square root of a covariance matrix, which was calculated from simulations.
For all DiffNet training and analysis, we used a split architecture (as described previously)
where the classification task was focused on all atoms within 1nm of SAM or RNA-cap
based on 6wks crystal structure. This atom selection was chosen to guide DiffNets to find
differences in the active site region of Nsp16, which is inherently linked to its activation.
For training, simulation frames are classified as ‚ÄúNsp16 inactive‚Äù or ‚ÄúNsp16 active‚Äù based
on initial classification labels of 0 (i.e. Nsp16 inactive) for all monomeric Nsp16 frames,
and labels of 1 (i.e. Nsp16 active) for all frames from the Nsp10/Nsp16 complex. These
labels were iteratively updated in a self-supervised manner described in the original
manuscript where we choose expectation maximization bounds of [0.1-0.4] for
monomeric Nsp16 and [0.6-0.9] for the Nsp10/Nsp16 complex. This allows for more
coherent classification labels as monomeric Nsp16 may sometimes adopt structural
poses associated with Nsp16 activation and vice-versa for the Nsp10-Nsp16 complex.
Additionally, we used 30 latent variables, 10 training epochs where we subsampled the
data by a factor of 10 in each epoch, a batch size of 32, and a learning rate of 0.0001.
To analyze the DiffNet output, we calculated 10 representative structures that span
from ‚ÄúNsp16 inactive‚Äù states to ‚ÄúNsp16 active‚Äù states (i.e. structures with classification
labels spanning 0 to 1). After training, the DiffNet learns a low-dimensional representation
of each simulation frame (i.e. a latent vector) and outputs a classification label for every
simulation frame. We binned the structures into 10 equally spaced bins based on their
classification labels, which span from 0-1. The, we calculated the mean latent vector for
each bin and used the DiffNet to reconstruct a structure based on each latent vector.
These structures were used as representative structures for each bin. All training and
analysis were performed using the open-source package https://github.com/bowmanlab/diffnets.
Markov State Models
A Markov State Model (MSM) is a statistical framework for analyzing molecular dynamics
simulations that provides a network representation of a free energy landscape. (37, 48,
49) To quantify cryptic pocket opening across the homologs and changes between
monomeric Nsp16 and the Nsp10/Nsp16 complex, we performed several measurements
that rely on MSMs built based on the simulation data. We built a separate MSM for each
system using all simulation data available for that system. All MSMs were constructed
with the Enspara python package (50). First, the solvent accessible surface area (SASA)

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

of each residue side-chain was calculated using the Shrake-Rupley algorithm (51)
implemented in MDTraj (52) using a drug-sized probe (2.8 AÃä sphere).
Then, we clustered the data using a hybrid clustering algorithm. First, we used a
k-centers algorithm (53) to cluster the data (5000 clusters for SARS-CoV-2 data, 1500
clusters for each other homolog). Next, we applied sweeps of k-medoids update steps (3
for SARS-CoV-2 data, 2 for other homologs) which refined the cluster centers to be in the
densest regions of conformational space (54). A Markov time of 5 ns was selected for
based on the implied timescales to build a Markov state model (MSM) for each homolog.
To build the MSMs, transition probability matrices were produced by counting transitions
1
between states (i.e. clusters), adding a prior count of ùëÅ
and row-normalizing, as is
ùë†ùë°ùëéùë°ùëíùë†

described previously (55). Equilibrium populations were calculated as the eigenvector of
the transition probability matrix with an eigenvalue of one. For all histograms shown, we
calculated the order parameter of distance (e.g. distance between Œ≤3-Œ≤4) using cluster
centers (i.e. representative structure of the cluster) and weighted the order parameter by
the corresponding equilibrium population calculated with the MSM. We also resampled
the equilibrium populations 100 times by bootstrapping the MSM, which provided error
bars for computing the fraction of SAM and RNA compatible states adopted by
monomeric Nsp16 and the Nsp16/10 complex.
Distance and SASA calculations
Figures 2, 3, and 4 include distance and SASA measurements that are explained in more
detail here. In Figure 2 we measure the distance between gate loop 1 and gate loop 2 as
the distance between Gln28 and Lys141 since these residues are known to undergo
significant changes for RNA binding. We measure the distance between SAM binding
loop 2 and gate loop 2 as the average distance between (Met131, Tyr132, Asp133,
Pro134) and (Asp99, Leu100, Asn101, Asp102) as these are key residues that cradle
SAM in the bound state. All SASA measurements are performed using Ala79, Thr82,
Ala83, Leu86, Thr93, Leu94, Leu95, Val96, Asp97, Ala98 and Asp99 as this is the main
component that gets exposed during cryptic pocket opening.
Cryptic pocket detection
Cryptic pockets in SARS-CoV2 Nsp16 were identified using our previously established
approach called Exposons analysis (38). This analysis was performed using the cluster
centers and the equilibrium probabilities derived from the MSMs built on the residue level
SASA described above. The center of each cluster was taken as an exemplar of that
conformational state, and residues were classified as exposed if their SASA exceeded
2.0 AÃä2 and buried otherwise. The mutual information between the exposure/burial of each
residue-pair was calculated based on the MSM, by treating the SASA values in the cluster
centers as samples and weighting them by the equilibrium probability of the
representative state. The mutual information was computed using the following equation:

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

ùëÄùêº(ùëã, ùëå) = ‚àë ‚àë ùëù(ùë•, ùë¶)ùëôùëúùëî (
ùë•‚ààùëã ùë¶‚ààùëå

ùëù(ùë•, ùë¶)
)
ùëù(ùë•)ùëù(ùë¶)

Finally, cryptic pockets (Exposons) were identified as groups of residues undergoing
cooperative change in SASA, by clustering the matrix of pairwise mutual information using
affinity propagation.
The Œ≤3-Œ≤4 cryptic pocket identified in SARS-CoV2 Nsp16 consists of residues
Ala79, Thr82, Ala83, Leu86, Thr93, Leu94, Leu95, Val96, Asp97, Ala98 and Asp99. Total
SASA of these residues/homologous residues was measured for detecting cryptic pocket
opening in all homologs of Nsp16 (SARS-CoV2, SARS-CoV1 and MERS). For measuring
equivalent cryptic pocket in CMTR1, total SASA of structurally homologous residues
(Gly141, Ser144, Glu145, Val148, Ala155, Lys156, Gly157, His158, Gly159, Met160,
Thr161) was calculated.

Sequence Conservation
Protein sequences of Nsp16 from SARS-CoV2 (YP_009725311.1), SARS-CoV1 (Uniprot
ID: P0C6X7), MERS (Uniprot ID: K0BWD0), NL63 (AFD64750.1), HKU1 (YP_460023.1),
Turkey CoV (YP_001941189.1), Bat CoV (YP_008439226.1), Murine hepatitis virus
(YP_209243.1) were used for multiple sequence alignment. Sequences alignment was
performed on Clustal Omega server (56). Sequence alignment was visualized, and the
sequence conservation score was generated using Jalview 2 software (57).
For sequence comparison of SARS-CoV2, SARS-CoV1, MERS and human
CMTr1 shown in Fig. 4, structure-based sequence alignment was performed using UCSF
Chimera package (58). For the structure-based sequence alignment, we first aligned the
structures of these homologs (PDB: 6wks (SARS-CoV2), 3r24 (SARS-CoV2), 5ynf
(MERS) and 4n49 (CMTr1). Then, the sequences were aligned based on the structural
alignment of the backbone atoms.

Author Contributions: NV, MDW, SS, GRB designed the research. NV, MDW, MIZ,
BN, JHB, and SS performed research. NV, MDW, JHB, and GRB wrote the manuscript.
Conflicts of Interest: The authors declare no conflicts of interest.
Acknowledgements:
We are grateful to the citizen scientists who contribute to Folding@home by running
simulations on their personal computers. This work was funded by NSF CAREER Award
MCB-1552471, NSF RAPID 58628, and NIH R01 GM124007. GRB holds a Career Award
at the Scientific Interface from the Burroughs Wellcome Fund and a Packard Fellowship
for Science and Engineering from The David & Lucile Packard Foundation. We are

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

grateful to Catherine Knoverek for her thoughtful feedback when editing initial drafts of
the writing.

References
1.

2.

3.

4.
5.
6.

7.

8.
9.
10.

11.

12.

Zhou, P., X. Lou Yang, X.G. Wang, B. Hu, L. Zhang, W. Zhang, H.R. Si, Y. Zhu, B.
Li, C.L. Huang, H.D. Chen, J. Chen, Y. Luo, H. Guo, R. Di Jiang, M.Q. Liu, Y. Chen,
X.R. Shen, X. Wang, X.S. Zheng, K. Zhao, Q.J. Chen, F. Deng, L.L. Liu, B. Yan,
F.X. Zhan, Y.Y. Wang, G.F. Xiao, and Z.L. Shi. 2020. A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature. 579: 270‚Äì273.
Zimmerman, M.I., J.R. Porter, M.D. Ward, S. Singh, N. Vithani, A. Meller, U.L.
Mallimadugula, C.E. Kuhn, J.H. Borowsky, R.P. Wiewiora, M.F.D. Hurley, A.M.
Harbison, C.A. Fogarty, J.E. Coffland, E. Fadda, V.A. Voel, J.D. Chodera, and G.R.
Bowman. 2020. SARS-CoV-2 Simulations Go Exascale to Capture Spike Opening
and Reveal Cryptic Pockets Across the Proteome. bioRxiv. .
Wu, A., Y. Peng, B. Huang, X. Ding, X. Wang, P. Niu, J. Meng, Z. Zhu, Z. Zhang,
J. Wang, J. Sheng, L. Quan, Z. Xia, W. Tan, G. Cheng, and T. Jiang. 2020. Genome
Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in
China. Cell Host Microbe. 27: 325‚Äì328.
Johns Hopkins Coronavirus Resource Center. 2020. COVID-19 Map. Johns
Hopkins Coronavirus Resour. Center-Johns Hopkins Univ. Med. .
Chan-Yeung, M., and R.H. Xu. 2003. SARS: Epidemiology. Respirology. 8 Suppl:
S9-14.
Zaki, A.M., S. van Boheemen, T.M. Bestebroer, A.D.M.E. Osterhaus, and R.A.M.
Fouchier. 2012. Isolation of a Novel Coronavirus from a Man with Pneumonia in
Saudi Arabia. N. Engl. J. Med. 367: 1814‚Äì1820.
Chan, J.F.W., K.K.W. To, H. Tse, D.Y. Jin, and K.Y. Yuen. 2013. Interspecies
transmission and emergence of novel viruses: Lessons from bats and birds. Trends
Microbiol. 21: 544‚Äì55.
Belete, T.M. 2020. A review on Promising vaccine development progress for
COVID-19 disease. Vacunas. 21: 121‚Äì128.
Callaway, E. 2020. COVID vaccine excitement builds as Moderna reports third
positive result. Nature. 587: 337‚Äì338.
Jackson, L.A., E.J. Anderson, N.G. Rouphael, P.C. Roberts, M. Makhene, R.N.
Coler, M.P. McCullough, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers,
A. McDermott, B. Flach, N.A. Doria-Rose, K.S. Corbett, K.M. Morabito, S. O‚ÄôDell,
S.D. Schmidt, P.A. Swanson, M. Padilla, J.R. Mascola, K.M. Neuzil, H. Bennett, W.
Sun, E. Peters, M. Makowski, J. Albert, K. Cross, W. Buchanan, R. Pikaart-Tautges,
J.E. Ledgerwood, B.S. Graham, and J.H. Beigel. 2020. An mRNA Vaccine against
SARS-CoV-2 ‚Äî Preliminary Report. N. Engl. J. Med. 383: 1920‚Äì1931.
Huang, Y., C. Yang, X. feng Xu, W. Xu, and S. wen Liu. 2020. Structural and
functional properties of SARS-CoV-2 spike protein: potential antivirus drug
development for COVID-19. Acta Pharmacol. Sin. 41: 1141‚Äì1149.
da Silva, S.J.R., C.T. Alves da Silva, R.P.G. Mendes, and L. Pena. 2020. Role of
nonstructural proteins in the pathogenesis of SARS-CoV-2. J. Med. Virol. 92: 1427‚Äì

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

13.
14.
15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

1429.
Snijder, E.J., E. Decroly, and J. Ziebuhr. 2016. The Nonstructural Proteins Directing
Coronavirus RNA Synthesis and Processing. Adv. Virus Res. 96: 59‚Äì126.
Ramanathan, A., G.B. Robb, and S.H. Chan. 2016. mRNA capping: Biological
functions and applications. Nucleic Acids Res. 44: 7511‚Äì7526.
Daffis, S., K.J. Szretter, J. Schriewer, J. Li, S. Youn, J. Errett, T.Y. Lin, S. Schneller,
R. Zust, H. Dong, V. Thiel, G.C. Sen, V. Fensterl, W.B. Klimstra, T.C. Pierson, R.M.
Buller, M. Gale Jr, P.Y. Shi, and M.S. Diamond. 2010. 2‚Ä≤-O methylation of the viral
mRNA cap evades host restriction by IFIT family members. Nature. 468: 452‚Äì456.
Decroly, E., I. Imbert, B. Coutard, M. Bouvet, B. Selisko, K. Alvarez, A.E.
Gorbalenya, E.J. Snijder, and B. Canard. 2008. Coronavirus Nonstructural Protein
16 Is a Cap-0 Binding Enzyme Possessing (Nucleoside-2‚Ä≤O)-Methyltransferase
Activity. J. Virol. 82: 8071‚Äì8084.
Sawicki, S.G., D.L. Sawicki, D. Younker, Y. Meyer, V. Thiel, H. Stokes, and S.G.
Siddell. 2005. Functional and genetic analysis of coronavirus replicasetranscriptase proteins. PLoS Pathog. 1: e39.
Chen, Y., C. Su, M. Ke, X. Jin, L. Xu, Z. Zhang, A. Wu, Y. Sun, Z. Yang, P. Tien, T.
Ahola, Y. Liang, X. Liu, and D. Guo. 2011. Biochemical and structural insights into
the mechanisms of sars coronavirus RNA ribose 2‚Ä≤-O-methylation by nsp16/nsp10
protein complex. PLoS Pathog. 7: e1002294.
Decroly, E., C. Debarnot, F. Ferron, M. Bouvet, B. Coutard, I. Imbert, L. Gluais, N.
Papageorgiou, A. Sharff, G. Bricogne, M. Ortiz-Lombardia, J. Lescar, and B.
Canard. 2011. Crystal structure and functional analysis of the SARS-coronavirus
RNA cap 2‚Ä≤-o-methyltransferase nsp10/nsp16 complex. PLoS Pathog. 7:
e1002059.
Menachery, V.D., K. Debbink, and R.S. Baric. 2014. Coronavirus non-structural
protein 16: Evasion, attenuation, and possible treatments. Virus Res. 194: 191‚Äì
199.
Smietanski, M., M. Werner, E. Purta, K.H. Kaminska, J. Stepinski, E.
Darzynkiewicz, M. Nowotny, and J.M. Bujnicki. 2014. Structural analysis of human
2‚Ä≤-O-ribose methyltransferases involved in mRNA cap structure formation. Nat.
Commun. 5: 3004.
Hodel, A.E., P.D. Gershon, and F.A. Quiocho. 1998. Structural basis for sequencenonspecific recognition of 5‚Ä≤-Capped mRNA by a cap-modifying enzyme. Mol. Cell.
1: 443‚Äì447.
Bouvet, M., C. Debarnot, I. Imbert, B. Selisko, E.J. Snijder, B. Canard, and E.
Decroly. 2010. In vitro reconstitution of sars-coronavirus mRNA cap methylation.
PLoS Pathog. 6: e1000863.
Rosas-Lemus, M., G. Minasov, L. Shuvalova, N. Inniss, O. Kiryukhina, G. Wiersum,
Y. Kim, R. Jedrzejczak, N. Maltseva, M. Endres, L. Jaroszewski, A. Godzik, A.
Joachimiak, and K. Satchell. 2020. The crystal structure of nsp10-nsp16
heterodimer from SARS-CoV-2 in complex with S-adenosylmethionine. bioRxiv
Prepr. Serv. Biol. .
Viswanathan, T., S. Arya, S.H. Chan, S. Qi, N. Dai, A. Misra, J.G. Park, F. Oladunni,
D. Kovalskyy, R.A. Hromas, L. Martinez-Sobrido, and Y.K. Gupta. 2020. Structural
basis of RNA cap modification by SARS-CoV-2. Nat. Commun. 11: 3718.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

26.

27.

28.

29.

30.
31.

32.

33.

34.

35.

36.

37.
38.

39.

Lin, S., H. Chen, F. Ye, Z. Chen, F. Yang, Y. Zheng, Y. Cao, J. Qiao, S. Yang, and
G. Lu. 2020. Crystal structure of SARS-CoV-2 nsp10/nsp16 2‚Ä≤-O-methylase and its
implication on antiviral drug design. Signal Transduct. Target. Ther. 5: 5‚Äì8.
Debarnot, C., I. Imbert, F. Ferron, L. Gluais, I. Varlet, N. Papageorgiou, M. Bouvet,
J. Lescar, E. Decroly, and B. Canard. 2011. Crystallization and diffraction analysis
of the SARS coronavirus nsp10-nsp16 complex. Acta Crystallogr. Sect. F Struct.
Biol. Cryst. Commun. 67: 404‚Äì408.
Krafcikova, P., J. Silhan, R. Nencka, and E. Boura. 2020. Structural analysis of the
SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to
sinefungin. Nat. Commun. 11: 3717.
Khan, R.J., R.K. Jha, G.M. Amera, M. Jain, E. Singh, A. Pathak, R.P. Singh, J.
Muthukumaran, and A.K. Singh. 2020. Targeting SARS-CoV-2: a systematic drug
repurposing approach to identify promising inhibitors against 3C-like proteinase
and 2‚Ä≤-O-ribose methyltransferase. J. Biomol. Struct. Dyn. : 1‚Äì14.
Petrossian, T.C., and S.G. Clarke. 2011. Uncovering the human
methyltransferasome. Mol. Cell. Proteomics. 10: M110.000976.
Wang, Y., Y. Sun, A. Wu, S. Xu, R. Pan, C. Zeng, X. Jin, X. Ge, Z. Shi, T. Ahola,
Y. Chen, and D. Guo. 2015. Coronavirus nsp10/nsp16 Methyltransferase Can Be
Targeted by nsp10-Derived Peptide In Vitro and In Vivo To Reduce Replication and
Pathogenesis. J. Virol. 89: 8416‚Äì8427.
Ke, M., Y. Chen, A. Wu, Y. Sun, C. Su, H. Wu, X. Jin, J. Tao, Y. Wang, X. Ma, J.A.
Pan, and D. Guo. 2012. Short peptides derived from the interaction domain of
SARS coronavirus nonstructural protein nsp10 can suppress the 2‚Äô-Omethyltransferase activity of nsp10/nsp16 complex. Virus Res. 167: 322‚Äì328.
Lee, A.C.L., J.L. Harris, K.K. Khanna, and J.H. Hong. 2019. A comprehensive
review on current advances in peptide drug development and design. Int. J. Mol.
Sci. 20: 2383.
Joseph, J.S., K.S. Saikatendu, V. Subramanian, B.W. Neuman, A. Brooun, M.
Griffith, K. Moy, M.K. Yadav, J. Velasquez, M.J. Buchmeier, R.C. Stevens, and P.
Kuhn. 2006. Crystal Structure of Nonstructural Protein 10 from the Severe Acute
Respiratory Syndrome Coronavirus Reveals a Novel Fold with Two Zinc-Binding
Motifs. J. Virol. 80: 7894‚Äì901.
Zimmerman, M.I., and G.R. Bowman. 2015. FAST Conformational Searches by
Balancing Exploration/Exploitation Trade-Offs. J. Chem. Theory Comput. 11:
5747‚Äì5757.
Ward, M.D., M.I. Zimmerman, S.J. Swamidass, and G.R. Bowman. 2020. DiffNets:
Self-supervised deep learning to identify the mechanistic basis for biochemical
differences between protein variants. bioRxiv. .
Bowman, G.R., V.S. Pande, and F. No√©. 2014. An Introduction to Markov State
Models and Their Application to Long Timescale Molecular Simulation. Springer. .
Porter, J.R., K.E. Moeder, C.A. Sibbald, M.I. Zimmerman, K.M. Hart, M.J.
Greenberg, and G.R. Bowman. 2019. Cooperative Changes in Solvent Exposure
Identify Cryptic Pockets, Switches, and Allosteric Coupling. Biophys. J. 116: 818‚Äì
830.
≈†ali, A., and T.L. Blundell. 1993. Comparative protein modelling by satisfaction of
spatial restraints. J. Mol. Biol. 234: 779‚Äì815.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

40.

41.
42.
43.

44.
45.
46.

47.

48.
49.
50.

51.
52.

53.
54.
55.

56.

57.

Jorgensen, W.L., J. Chandrasekhar, J.D. Madura, R.W. Impey, and M.L. Klein.
1983. Comparison of simple potential functions for simulating liquid water. J. Chem.
Phys. 79: 926‚Äì935.
Hess, B. 2008. P-LINCS: A parallel linear constraint solver for molecular simulation.
J. Chem. Theory Comput. 4: 116‚Äì122.
Darden, T., D. York, and L. Pedersen. 1993. Particle mesh Ewald: An N ‚ãÖlog( N )
method for Ewald sums in large systems. J. Chem. Phys. 98: 10089‚Äì10092.
Berendsen, H.J.C., J.P.M. Postma, W.F. Van Gunsteren, A. Dinola, and J.R. Haak.
1984. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81:
3684‚Äì3690.
Bussi, G., D. Donadio, and M. Parrinello. 2007. Canonical sampling through velocity
rescaling. J. Chem. Phys. 126: 014101.
Zimmerman, M.I., and G.R. Bowman. 2016. How to Run FAST Simulations.
Methods Enzymol. 578: 213‚Äì225.
Zimmerman, M.I., K.M. Hart, C.A. Sibbald, T.E. Frederick, J.R. Jimah, C.R.
Knoverek, N.H. Tolia, and G.R. Bowman. 2017. Prediction of New Stabilizing
Mutations Based on Mechanistic Insights from Markov State Models. ACS Cent.
Sci. 3: 1311‚Äì1321.
Hendlich, M., F. Rippmann, and G. Barnickel. 1997. LIGSITE: Automatic and
efficient detection of potential small molecule-binding sites in proteins. J. Mol.
Graph. Model. 15: 359‚Äì363.
Chodera, J.D., and F. No√©. 2014. Markov state models of biomolecular
conformational dynamics. Curr. Opin. Struct. Biol. 25: 135‚Äì144.
Sch√ºtte, C., and M. Sarich. 2015. A critical appraisal of Markov state models. Eur.
Phys. J. Spec. Top. 224: 2445‚Äì2462.
Porter, J.R., M.I. Zimmerman, and G.R. Bowman. 2019. Enspara: Modeling
molecular ensembles with scalable data structures and parallel computing. J.
Chem. Phys. 150: 044108.
Shrake, A., and J.A. Rupley. 1973. Environment and exposure to solvent of protein
atoms. Lysozyme and insulin. J. Mol. Biol. 79: 351‚Äì371.
McGibbon, R.T., K.A. Beauchamp, M.P. Harrigan, C. Klein, J.M. Swails, C.X.
Hern√°ndez, C.R. Schwantes, L.P. Wang, T.J. Lane, and V.S. Pande. 2015. MDTraj:
A Modern Open Library for the Analysis of Molecular Dynamics Trajectories.
Biophys. J. 109: 1528‚Äì1532.
Gonzalez, T.F. 1985. Clustering to minimize the maximum intercluster distance.
Theor. Comput. Sci. 38: 293‚Äì306.
Gentle, J.E., L. Kaufman, and P.J. Rousseuw. 1991. Finding Groups in Data: An
Introduction to Cluster Analysis. Biometrics. .
Zimmerman, M.I., J.R. Porter, X. Sun, R.R. Silva, and G.R. Bowman. 2018. Choice
of Adaptive Sampling Strategy Impacts State Discovery, Transition Probabilities,
and the Apparent Mechanism of Conformational Changes. J. Chem. Theory
Comput. 14: 5459‚Äì5475.
Madeira, F., Y.M. Park, J. Lee, N. Buso, T. Gur, N. Madhusoodanan, P. Basutkar,
A.R.N. Tivey, S.C. Potter, R.D. Finn, and R. Lopez. 2019. The EMBL-EBI search
and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47: W636‚ÄìW641.
Waterhouse, A.M., J.B. Procter, D.M.A. Martin, M. Clamp, and G.J. Barton. 2009.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

58.

Jalview Version 2-A multiple sequence alignment editor and analysis workbench.
Bioinformatics. 25: 1189‚Äì1191.
Pettersen, E.F., T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C.
Meng, and T.E. Ferrin. 2004. UCSF Chimera - A visualization system for
exploratory research and analysis. J. Comput. Chem. 25: 1605‚Äì1612.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Supporting Information for SARS-CoV-2 Nsp16 activation mechanism and a
cryptic pocket with pan-coronavirus antiviral potential
Neha Vithani1,2*, Michael D. Ward1,2*, Maxwell I. Zimmerman1,2, Borna Novak1,2,3,
Jonathan H. Borowsky1,2, Sukrit Singh1,2, Gregory R. Bowman1,2‚Ä†
1Department

of Biochemistry and Molecular Biophysics, Washington University School of
Medicine, St. Louis, Missouri 63110, United States
2Center for Science and Engineering of Living Systems (CSELS), Washington University
in St. Louis, St. Louis, Missouri 63130, United States
3Medical Scientist Training Program, Washington University in St. Louis School of
Medicine, St. Louis, Missouri 63110, United States

*These authors contributed equally to this work.
‚Ä†Corresponding Author: g.bowman@wustl.edu

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure S1. Change in root mean square fluctuation (rmsf) of Nsp16 upon Nsp10
association. (A) Probability weighted Œîrmsf of Nsp16‚Äô residues upon Nsp10 binding is
plotted. Negative values represent a decrease in rmsf upon Nsp10 binding. RNA binding
loops (gate loop 1 and 2) and SAM binding loops (SAMBL1 and 2) are highlighted by the
blue colored boxes. (B) Probability weighted Œîrmsf of Nsp16 is mapped on its structure,
with negative values shown in blue and positive values in red.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure S2. DiffNets predict that Œ≤4 peels away from Œ≤3 in Nsp16 inactive structural states.
(Left) Structural states changing from inactive to active (white to purple) as predicted by
the DiffNet. (Right) The loop connecting Œ≤3 and Œ≤4 peels away from Œ≤3 into solution in
predicted inactive states.

Figure S3. Displacement of Nsp10 binding residues by cryptic pocket opening. (A)
Structure of Nsp16 in cryptic pocket closed state is shown in grey. Cryptic pocket forming
residues and the residues undergoing opening motion are shown in cyan and blue,
respectively. Cryptic pocket residues that contact Nsp10 are depicted in spheres. (B)
Opening motion of the cryptic pocket shows the displacement of Nsp10 binding residues.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.10.420109; this version posted December 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure S4. Structural comparison of Œ≤3-Œ≤4 cryptic pocket in SARS-CoV2 Nsp16 and
human CMTr1. (A) Œ≤3 and residues lining the cryptic pocket in SARS-CoV2 are shown in
cyan and blue, respectively. (B) Regions of human CMTr1, structurally equivalent to Œ≤3
and the pocket lining regions are depicted in cyan and blue, respectively.

Figure S5. Multiple sequence alignment of Nsp16 homologs from coronaviruses. The
color ranges from white to orange for the sequence conservation score ranging from 0 to
10, where 10 denotes 100% sequence identity. Residues of Íûµ3 are enclosed in the black
box. Uniprot ids of the sequences used for the alignment are given in the Methods section.

